1
|
Leite JP, Lete MG, Fowler SB, Gimeno A, Rocha JF, Sousa SF, Webster CI, Jiménez-Bar̀bero JJ, Gales L. Aβ 31-35 Decreases Neprilysin-Mediated Alzheimer's Amyloid-β Peptide Degradation. ACS Chem Neurosci 2021; 12:3708-3718. [PMID: 34505762 DOI: 10.1021/acschemneuro.1c00432] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Alzheimer's disease is associated with the deposition of extracellular senile plaques, made primarily of amyloid-β (Aβ), particularly peptides Aβ1-42 and Aβ1-40. Neprilysin, or neutral endopeptidase (NEP), catalyzes proteolysis of the amyloid peptides (Aβ) and is recognized as one of the major regulators of the levels of these peptides in the brain, preventing Aβ accumulation and plaque formation. Here, we used a combination of techniques to elucidate the mechanism of Aβ binding and cleavage by NEP. Our findings indicate that the Aβ31-X cleavage products remain bound to the neprilysin active site, reducing proteolytic activity. Interestingly, it was already shown that this Aβ31-35 sequence is also critical for recognition of Aβ peptides by other targets, such as the serpin-enzyme complex receptor in neuronal cells.
Collapse
Affiliation(s)
- José P. Leite
- i3S—Instituto de Investigação e Inovação em Saúde, Rua Alfredo Allen, 208, Porto 4200-135, Portugal
- IBMC—Instituto de Biologia Molecular e Celular, Universidade do Porto, Rua Alfredo Allen, 208, Porto 4200-135, Portugal
- Programa Doutoral em Biologia Molecular e Celular (MCbiology), ICBAS—Instituto de Ciências Biomédicas Abel Salazar, Rua de Jorge Viterbo Ferreira 228, Porto 4050-313, Portugal
- ICBAS—Instituto de Ciências Biomédicas Abel Salazar, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal
| | - Marta G. Lete
- CIC bioGUNE, Bizkaia Technology Park, Building 801A, Derio 48170, Spain
| | - Susan B. Fowler
- Antibody Discovery & Protein Engineering R&D, AstraZeneca, Cambridge CB21 6GH, U.K
| | - Ana Gimeno
- CIC bioGUNE, Bizkaia Technology Park, Building 801A, Derio 48170, Spain
| | - Juliana F. Rocha
- UCIBIO/REQUIMTE, BioSIM-Department of Biomedicine, Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, Porto 4200-319, Portugal
| | - Sérgio F. Sousa
- UCIBIO/REQUIMTE, BioSIM-Department of Biomedicine, Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, Porto 4200-319, Portugal
| | - Carl I. Webster
- Antibody Discovery & Protein Engineering R&D, AstraZeneca, Cambridge CB21 6GH, U.K
| | - Jesús J. Jiménez-Bar̀bero
- CIC bioGUNE, Bizkaia Technology Park, Building 801A, Derio 48170, Spain
- Ikerbasque, Basque Foundation for Science, Bilbao 48013, Spain
- Department of Organic Chemistry II, Faculty of Science and Technology, UPV-EHU, 48940 Leioa, Spain
| | - Luís Gales
- i3S—Instituto de Investigação e Inovação em Saúde, Rua Alfredo Allen, 208, Porto 4200-135, Portugal
- IBMC—Instituto de Biologia Molecular e Celular, Universidade do Porto, Rua Alfredo Allen, 208, Porto 4200-135, Portugal
- ICBAS—Instituto de Ciências Biomédicas Abel Salazar, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal
| |
Collapse
|
2
|
Liang WG, Mancl JM, Zhao M, Tang WJ. Structural analysis of Mycobacterium tuberculosis M13 metalloprotease Zmp1 open states. Structure 2020; 29:709-720.e3. [PMID: 33378640 DOI: 10.1016/j.str.2020.12.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Revised: 10/12/2020] [Accepted: 12/04/2020] [Indexed: 12/16/2022]
Abstract
Zinc metalloprotease 1 (Zmp1), a Mycobacterium tuberculosis 75 kDa secreted enzyme, mediates key stages of tuberculosis disease progression. The biological activity of Zmp1 presumably stems from its ability to degrade bacterium- and/or host-derived peptides. The crystal structures of Zmp1 and related M13 metalloproteases, such as neprilysin and endothelin-converting enzyme-1 were determined only in the closed conformation, which cannot capture substrates or release proteolytic products. Thus, the mechanisms of substrate binding and selectivity remain elusive. Here we report two open-state cryo-EM structures of Zmp1, revealed by our SAXS analysis to be the dominant states in solution. Our structural analyses reveal how ligand binding induces a conformational switch in four linker regions to drive the rigid body motion of the D1 and D2 domains, which form the sizable catalytic chamber. Furthermore, they offer insights into the catalytic cycle and mechanism of substrate recognition of M13 metalloproteases for future therapeutic innovations.
Collapse
Affiliation(s)
- Wenguang G Liang
- Ben May Department for Cancer Research, The University of Chicago, Chicago, IL 60637, USA
| | - Jordan M Mancl
- Ben May Department for Cancer Research, The University of Chicago, Chicago, IL 60637, USA
| | - Minglei Zhao
- Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago, IL 60637, USA.
| | - Wei-Jen Tang
- Ben May Department for Cancer Research, The University of Chicago, Chicago, IL 60637, USA.
| |
Collapse
|
3
|
Sharma U, Cozier GE, Sturrock ED, Acharya KR. Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme. J Med Chem 2020; 63:5488-5500. [PMID: 32337993 PMCID: PMC7304895 DOI: 10.1021/acs.jmedchem.0c00441] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
![]()
Neprilysin
(NEP) and angiotensin-converting enzyme (ACE) are two
key zinc-dependent metallopeptidases in the natriuretic peptide and
kinin systems and renin–angiotensin–aldosterone system,
respectively. They play an important role in blood pressure regulation
and reducing the risk of heart failure. Vasopeptidase inhibitors omapatrilat
and sampatrilat possess dual activity against these enzymes by blocking
the ACE-dependent conversion of angiotensin I to the potent vasoconstrictor
angiotensin II while simultaneously halting the NEP-dependent degradation
of vasodilator atrial natriuretic peptide. Here, we report crystal
structures of omapatrilat, sampatrilat, and sampatrilat-ASP (a sampatrilat
analogue) in complex with NEP at 1.75, 2.65, and 2.6 Å, respectively.
A detailed analysis of these structures and the corresponding structures
of ACE with these inhibitors has provided the molecular basis of dual
inhibitor recognition involving the catalytic site in both enzymes.
This new information will be very useful in the design of safer and
more selective vasopeptidase inhibitors of NEP and ACE for effective
treatment in hypertension and heart failure.
Collapse
Affiliation(s)
- Urvashi Sharma
- Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, United Kingdom
| | - Gyles E Cozier
- Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, United Kingdom
| | - Edward D Sturrock
- Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, 7935 Cape Town, Republic of South Africa
| | - K Ravi Acharya
- Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, United Kingdom
| |
Collapse
|